| Telmisartan, Amlodipine |
EU/1/10/648/016 |
TWYNSTA, Tablet, 80mg/ 5 mg, mg, Pack: 28 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
34.5 |
6.9 |
41.4 |
4% |
1.38 |
35.88 |
7.18 |
43.06 |
16% |
5.52 |
41.4 |
8.28 |
49.68 |
|
КЦРР-2603/14.03.2013 |
29.03.2013 |
29.03.2013 |
Неактивен |
3098 |
| Telmisartan, Amlodipine |
EU/1/10/648/023 |
TWYNSTA, Tablet, 80mg/ 10 mg, mg, Pack: 28 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
34.21 |
6.84 |
41.05 |
4% |
1.37 |
35.58 |
7.12 |
42.7 |
16% |
5.47 |
41.05 |
8.21 |
49.26 |
|
КЦРР-2604/14.03.2013 |
29.03.2013 |
29.03.2013 |
Неактивен |
3330 |
| Telmisartan, Amlodipine |
EU/1/10/648/016 |
TWYNSTA, Tablet, 80mg/ 5 mg, mg, Pack: 28 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
45.67 |
9.13 |
54.8 |
4% |
1.83 |
47.5 |
9.5 |
57 |
16% |
7.31 |
54.81 |
10.96 |
65.77 |
|
КЦ-2444/07.07.2011 |
21.07.2011 |
21.07.2011 |
Неактивен |
3098 |
| Telmisartan, Amlodipine |
EU/1/10/648/023 |
TWYNSTA, Tablet, 80mg/ 10 mg, mg, Pack: 28 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
49.29 |
9.86 |
59.15 |
4% |
1.97 |
51.26 |
10.25 |
61.51 |
16% |
7.89 |
59.15 |
11.83 |
70.98 |
|
КЦ-2444/07.07.2011 |
21.07.2011 |
21.07.2011 |
Неактивен |
3330 |
| Tigecycline |
EU/1/06/336/001 |
Tygacil 10mg/ml-5ml, Powder for solution for infusion, 50, mg/5ml, Pack: 10 |
Pfizer Europe MA EEIG, Обединено Кралство |
Wyeth Pharmaceuticals, Великобритания |
770.03 |
154.01 |
924.04 |
4% |
10 |
780.03 |
156.01 |
936.04 |
16% |
25 |
805.03 |
161.01 |
966.04 |
|
НСР-6856/30.07.2015 |
14.08.2015 |
14.08.2015 |
Активен |
3316 |
| Tigecycline |
EU/1/06/336/001 |
Tygacil 10mg/ml-5ml, Powder for solution for infusion, 50, mg/5ml, Pack: 10 |
Pfizer Europe MA EEIG, Обединено Кралство |
Wyeth Pharmaceuticals, Великобритания |
770.03 |
154.01 |
924.04 |
4% |
10 |
780.03 |
156.01 |
936.04 |
16% |
25 |
805.03 |
161.01 |
966.04 |
|
НСР-6856/30.07.2015 |
14.08.2015 |
14.08.2015 |
Неактивен |
3316 |
| Tigecycline |
EU/1/06/336/001 |
Tygacil 10mg/ml-5ml, Powder for solution for infusion, 50, mg/5ml, Pack: 10 |
Pfizer Europe MA EEIG, Обединено Кралство |
Wyeth Pharmaceuticals, Великобритания |
779.28 |
155.86 |
935.14 |
4% |
10 |
789.28 |
157.86 |
947.14 |
16% |
25 |
814.28 |
162.86 |
977.14 |
|
НСР-4877/17.10.2014 |
03.11.2014 |
03.11.2014 |
Неактивен |
3316 |
| Tigecycline |
EU/1/06/336/001 |
Tygacil 10mg/ml-5ml, Powder for solution for infusion, 50, mg/5ml, Pack: 10 |
Pfizer Europe MA EEIG, Обединено Кралство |
Wyeth Pharmaceuticals, Великобритания |
788.65 |
157.73 |
946.38 |
4% |
10 |
798.65 |
159.73 |
958.38 |
16% |
25 |
823.65 |
164.73 |
988.38 |
|
НСР+2334/13.01.2014 |
28.01.2014 |
28.01.2014 |
Неактивен |
3316 |
| Tigecycline |
EU/1/06/336/001 |
Tygacil 10mg/ml-5ml, Powder for solution for infusion, 50, mg/5ml, Pack: 10 |
Pfizer Europe MA EEIG, Обединено Кралство |
Wyeth Pharmaceuticals, Великобритания |
819.24 |
163.85 |
983.09 |
4% |
10 |
829.24 |
165.85 |
995.09 |
16% |
25 |
854.24 |
170.85 |
1025.09 |
промяна на обстоятелства решение КЦPP-1459/02.10.2012 |
КЦРР-975/16.07.2012 |
12.09.2012 |
12.09.2012 |
Неактивен |
3316 |
| Tigecycline |
EU/1/06/336/001 |
Tygacil 10mg/ml-5ml, Powder for solution for infusion, 50, mg/5ml, Pack: 10 |
Wyeth Europa Ltd., Обединено Кралство |
Wyeth Pharmaceuticals, Великобритания |
892.74 |
178.55 |
1071.29 |
4% |
10 |
902.74 |
180.55 |
1083.29 |
16% |
25 |
927.74 |
185.55 |
1113.29 |
|
КЦ-397/07.01.2009 |
30.01.2009 |
30.01.2009 |
Неактивен |
3316 |
| Typhoid Polysaccaride Vaccine |
1354/28.12.2007 |
TYPHERIX, Solution for injection, 0,5 ml/1 dose, -, Pack: 1 pre-filled syrigne + 2 needels |
ГлаксоСмитКлайн ЕООД, България |
GlaxoSmithKline Biologicals, Belgium |
13.69 |
2.74 |
16.43 |
6% |
0.82 |
14.51 |
2.9 |
17.41 |
18% |
2.46 |
16.97 |
3.39 |
20.36 |
|
КЦ-1238/18.12.2009 |
06.01.2010 |
06.01.2010 |
Активен |
844 |
| Typhoid Polysaccaride Vaccine |
II-0654/21.09.2007 |
Typhim Vi, Solution for injection, 0,5 ml/1 dose, -, Pack: 1pre-filled syringe |
Sanofi Pasteur S.A., Франция |
Sanofi Pasteur S.A., France; Sanofi-Aventis, Унгария |
16.55 |
3.31 |
19.86 |
6% |
0.99 |
17.54 |
3.51 |
21.05 |
18% |
2.98 |
20.52 |
4.1 |
24.62 |
промяна на обстоятелства НСР-5489/23.01.2015 |
КЦ-723/16.03.2009 |
03.04.2009 |
03.04.2009 |
Активен |
668 |
| Bisoprolol |
20120281/04.06.2012 |
Tyrez, Film coated tablet, 5, mg, Pack: 30 |
Alkaloid – INT d.o.o., Словения |
Alkaloid – INT d.o.o., Šlandrova ulica 4, 1231 Ljubljana, Črnuče, Словения |
1.9 |
0.38 |
2.28 |
7% |
0.13 |
2.03 |
0.41 |
2.44 |
20% |
0.38 |
2.41 |
0.48 |
2.89 |
цената се заличава HCР-449/09.07.2013 |
КЦРР-1729/04.12.2012 г |
20.12.2012 |
20.12.2012 |
Заличен |
1475 |
| Bisoprolol |
20120282/04.06.2012 |
Tyrez, Film coated tablet, 10, mg, Pack: 30 |
Alkaloid – INT d.o.o., Словения |
Alkaloid – INT d.o.o., Šlandrova ulica 4, 1231 Ljubljana, Črnuče, Словения |
3.13 |
0.63 |
3.76 |
7% |
0.22 |
3.35 |
0.67 |
4.02 |
20% |
0.63 |
3.98 |
0.8 |
4.78 |
цената се заличава HCР-450/09.07.2013 |
КЦРР-1729/04.12.2012 г |
20.12.2012 |
20.12.2012 |
Заличен |
1476 |
| Bisoprolol |
20120280/04.06.2012 |
Tyrez, Film coated tablet, 2.5, mg, Pack: 30 |
Alkaloid – INT d.o.o., Словения |
Alkaloid – INT d.o.o., Šlandrova ulica 4, 1231 Ljubljana, Črnuče, Словения |
1.7 |
0.34 |
2.04 |
7% |
0.12 |
1.82 |
0.36 |
2.18 |
20% |
0.34 |
2.16 |
0.43 |
2.59 |
цената се заличава HCР-448/09.07.2013 |
КЦРР-1729/04.12.2012 г |
20.12.2012 |
20.12.2012 |
Заличен |
1474 |
| Natalizumab |
ЕU/1/06/346/001 |
TYSABRI, Concentrate for solution for infusion, 300 mg (20 mg/ml)-15 ml, -, Pack: 1 vial |
Biogen Idec Limited, Обединено Кралство |
Biogen Denmark Manufacturing ApS, Дания |
2416.76 |
483.35 |
2900.11 |
4% |
10 |
2426.76 |
485.35 |
2912.11 |
16% |
25 |
2451.76 |
490.35 |
2942.11 |
промяна на обстоятелства НСР-9437/01.06.2016 |
НСР-4940/22.10.2014; НСР-9972/29.07.2016 |
02.09.2016 |
02.09.2016 |
Активен |
3295 |
| Natalizumab |
ЕU/1/06/346/001 |
TYSABRI, Concentrate for solution for infusion, 300 mg (20 mg/ml)-15 ml, mg, Pack: 1 vial |
Biogen Idec Limited, Обединено Кралство |
Biogen Denmark Manufacturing ApS, Дания |
2465.83 |
493.17 |
2959 |
4% |
10 |
2475.83 |
495.17 |
2971 |
16% |
25 |
2500.83 |
500.17 |
3001 |
промяна на обстоятелства НСР-9437/01.06.2016 |
НСР-4940/22.10.2014 |
06.11.2014 |
06.11.2014 |
Неактивен |
3295 |
| Natalizumab |
ЕU/1/06/346/001 |
TYSABRI, Concentrate for solution for infusion, 300 mg (20 mg/ml)-15 ml, mg, Pack: 1 vial |
Elan Pharma International, Ирландия |
Biogen Idec Denmark Manufacturing ApS; Biogen Idec Alle 1 DK-3400 Hillerod, Denmark |
2465.83 |
493.17 |
2959 |
4% |
10 |
2475.83 |
495.17 |
2971 |
16% |
25 |
2500.83 |
500.17 |
3001 |
|
НСР-4940/22.10.2014 |
06.11.2014 |
06.11.2014 |
Неактивен |
3295 |
| Natalizumab |
ЕU/1/06/346/001 |
TYSABRI, Concentrate for solution for infusion, 300 mg (20 mg/ml)-15 ml, mg, Pack: 1 vial |
Elan Pharma International, Ирландия |
Biogen Idec Denmark Manufacturing ApS; Biogen Idec Alle 1 DK-3400 Hillerod, Denmark |
2556.45 |
511.29 |
3067.74 |
4% |
10 |
2566.45 |
513.29 |
3079.74 |
16% |
25 |
2591.45 |
518.29 |
3109.74 |
|
НСР-2748/17.02.2014 |
06.03.2014 |
06.03.2014 |
Неактивен |
3295 |
| Natalizumab |
ЕU/1/06/346/001 |
TYSABRI, Concentrate for solution for infusion, 300 mg (20 mg/ml)-15 ml, mg, Pack: 1 vial |
Elan Pharma International, Ирландия |
Biogen Idec Denmark Manufacturing ApS; Biogen Idec Alle 1 DK-3400 Hillerod, Denmark |
2598.14 |
519.63 |
3117.77 |
4% |
10 |
2608.14 |
521.63 |
3129.77 |
16% |
25 |
2633.14 |
526.63 |
3159.77 |
|
HCР-21/31.05.2013 |
02.06.2013 |
02.06.2013 |
Неактивен |
3295 |
| Natalizumab |
EU/1/06/346/001 |
TYSABRI, Concentrate for solution for infusion, 300 mg (20 mg/ml)-15 ml, mg, Pack: 1 vial |
Elan Pharma International, Ирландия |
Biogen Idec Denmark Manufacturing ApS Biogen Idec Allé 1 DK-3400 Hillerød, Дания |
2832.12 |
566.42 |
3398.54 |
4% |
10 |
2842.12 |
568.42 |
3410.54 |
16% |
25 |
2867.12 |
573.42 |
3440.54 |
|
КЦРР-1059/26.07.2012 |
10.08.2012 |
10.08.2012 |
Неактивен |
3295 |
| Natalizumab |
EU/1/06/346/001 |
TYSABRI, Concentrate for solution for infusion, 300 mg (20 mg/ml)-15 ml, mg, Pack: 1 vial |
Elan Pharma International, Ирландия |
Biogen Idec Denmark Manufacturing ApS / Biogen Idec Allé 1 / DK-3400 Hillerød, Дания |
2979.49 |
595.9 |
3575.39 |
6% |
15 |
2994.49 |
598.9 |
3593.39 |
18% |
30 |
3024.49 |
604.9 |
3629.39 |
|
КЦ-648/05.03.2009 |
19.03.2009 |
19.03.2009 |
Неактивен |
3295 |
| Lapatinib |
EU/1/07/440/002 |
Tyverb, Film coated tablet, 250, mg, Pack: 140 |
Glaxo Group Ltd., Обединено Кралство |
Glaxo Operations UK Ltd, UK |
4283.72 |
856.74 |
5140.46 |
6% |
15 |
4298.72 |
859.74 |
5158.46 |
18% |
30 |
4328.72 |
865.74 |
5194.46 |
Цената е заличена с решение КЦРР-932/04.07.2012 |
КЦ-328/28.11.2008 |
22.12.2008 |
22.12.2008 |
Заличен |
314 |
| Lapatinib |
EU/1/07/440/006 |
TYVERB, Film coated tablet, 250, mg, Pack: 84 |
Novartis Europharm Limited, Обединено Кралство |
Glaxo Operations UK Ltd., UK |
2380.56 |
476.11 |
2856.67 |
4% |
10 |
2390.56 |
478.11 |
2868.67 |
16% |
25 |
2415.56 |
483.11 |
2898.67 |
Промяна на обстоятелства НСР- 6990/24.08.2015; корекционно решение НСР7539/19.11.2015 |
КЦ-2824/04.10.2011 |
18.10.2011 |
18.10.2011 |
Активен |
1113 |
| Lapatinib |
EU/1/07/440/005 |
TYVERB, Film coated tablet, 250, mg, Pack: 140 |
Novartis Europharm Limited, Обединено Кралство |
Glaxo Operations UK Ltd., UK; Glaxo Wellcome S.A., Spain |
3550.36 |
710.07 |
4260.43 |
4% |
10 |
3560.36 |
712.07 |
4272.43 |
16% |
25 |
3585.36 |
717.07 |
4302.43 |
Промяна на обстоятелства НСР- 6733/16.07.2015; Протокол 130/06.8.2015; корекционно решение НСР7538/19.11.2015 |
НСР-5131/27.11.2014 |
12.12.2014 |
12.12.2014 |
Активен |
3392 |